Raymond James Financial Inc. bought a new stake in Sanofi in the fourth quarter valued at about $135,933,000. Boston Partners increased its holdings in Sanofi by 86.4% in the fourth quarter.
A new study led by researchers from Boston University Chobanian & Avedisian School of Medicine has found there is no consensus in how clinical experts interpret CGM reports from people without ...
Boston, USA-based biotech Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic ...
Flu vaccine makers may face a last-minute scramble to produce enough doses after an FDA advisory committee meeting was ...
12d
Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...
The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the ...
Don't miss out on Boston-area life science news ... Its latest deal is worth up to $1B Sanofi’s Framingham facility hit with FDA warning Sanofi’s Framingham facility hit with FDA warning ...
The use of digital twins with industrial, manufacturing and architectural use cases is well known, and in the manifold variety of use cases existing for digital twins, we can also include medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback